Patients with Parkinson's disease exhibiting impulse control disorders
Care Setting
Neurology and movement disorder specialty clinics
Key Highlights
Serotonergic alterations, including elevated serotonin transporter binding and increased 5-HT2A receptor availability, correlate with ICD severity and impulsivity subtypes in Parkinson’s disease.
Distinct neurobiological substrates underlie action (motor) and decision (choice) impulsivity, implicating sensorimotor and associative cortico-striato-pallido-thalamic circuits beyond dopaminergic pathways.
Serotonergic dysfunction may represent a predisposing factor for ICDs, suggesting potential for serotonin-based therapeutic interventions alongside dopaminergic management.
Guideline-Based Recommendations
Diagnosis
Consider assessment of impulsivity subtypes (action vs decision) in Parkinson’s disease patients presenting with ICDs.
Evaluate serotonergic system involvement as part of the neurobiological assessment of ICDs.
Management
Dopaminergic dose reduction alone may be insufficient; investigate adjunctive serotonin-based therapies or neuromodulatory approaches such as transcranial magnetic stimulation targeting the supplementary motor area.
Personalize treatment strategies based on genetic predisposition related to serotonergic function (e.g., TPH2 gene variants).
Monitoring & Follow-up
Monitor ICD severity and impulsivity subtypes longitudinally to assess treatment response.
Evaluate for premorbid risk factors including younger age at Parkinson’s onset, history of ICDs, depression, and substance abuse.
Risks
Chronic dopamine agonist therapy may impair negative feedback learning and reinforce compulsive behaviors.
Serotonergic deficits may predispose to more severe and persistent ICDs despite dopaminergic therapy adjustments.
Patient & Prescribing Data
Parkinson’s disease patients with impulse control disorders, particularly those with genetic or clinical markers of serotonergic dysfunction
Serotonin-based interventions and neuromodulation may offer therapeutic benefit beyond dopaminergic dose adjustments; genetic profiling may guide personalized treatment.
Clinical Best Practices
Incorporate evaluation of serotonergic dysfunction in the clinical assessment of ICDs in Parkinson’s disease.
Address both action and decision impulsivity in therapeutic planning.
Consider multimodal treatment approaches combining dopaminergic management with serotonin-targeted therapies and neuromodulation.
Screen for and consider individual vulnerability factors including genetic predisposition and premorbid psychiatric history.
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
